71 Prevention of rheumatoid arthritis Table 1 | Summary table of preventive interventional trials in individuals at risk of developing rheumatoid arthritis (continued) Trial name Inclusion criteria Number of patients (treatment vs placebo) Intervention Time of follow-up Primary outcome Secondary outcome Results Reference PROMPT study - UA 110 patients (55 treatment vs 55 placebo) 15 mg weekly methotrexate, increased every three months if DAS>2.4 - 3 months - 6 months - 9 months - 12 months - 18 months - 30 months - 5 years - Development of RA per 1987 ACR criteria - Radiographic joint damage progression of hand and feet at all timepoints except 3 months - Delay in ACPA-positive, but not ACPA-negative, patients with high risk of RA at 1 year - No significant difference in RA onset and radiographic progression at 5 years [49-52] SAVE study - Inflammatory arthritis <16 weeks 383 patients (198 treatment vs 185 placebo) 120 mg methylprednisolone at baseline - 12 weeks - 52 weeks - Clinical remission (no joint swelling, ≤2 tender joints, normalized CRP) - Additional use of glucocorticoids or DMARDs - No significant difference in remission (16.2% treatment vs 17.8% placebo) - Now difference in additional glucocorticoids (24.4% vs 27.0%) or DMARDs (43.4% vs 46.5%) [46] 4
RkJQdWJsaXNoZXIy MTk4NDMw